https://therivabio.com/press_releases/synthetic-biologics-announces-reverse-stock-split/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-first-quarter-2022-operational-highlights-and-financial-results/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-positive-safety-data-on-syn-020-intestinal-alkaline-phosphatase-phase-1-multiple-ascending-dose-clinical-trial/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2022-operational-highlights-and-financial-results/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-formation-of-scientific-advisory-board-to-advance-oncology-pipeline/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-presentation-on-vcn-11-a-novel-oncolytic-adenovirus-designed-to-evade-neutralizing-antibodies-at-the-upcoming-25th-annual-meeting-of-the-american-society-of-gene-cell/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-journal-for-immunotherapy-of-cancer-publication-of-phase-1-trial-of-intravenous-vcn-01-oncolytic-adenovirus-in-patients-with-advanced-solid-tumors/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-management-transitions-in-support-of-strategic-transformation/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-3-million-private-placement-of-convertible-preferred-stock/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-host-conference-call-and-webcast-to-discuss-second-quarter-2022-operational-highlights-and-financial-results/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-second-quarter-2022-operational-highlights-and-financial-results/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-presentation-at-esmo-congress-2022-describing-phase-1-investigator-sponsored-study-evaluating-vcn-01-in-combination-with-durvalumab-in-patients-with-recurrent-metastatic/ 2022-10-06T11:16:05+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-participate-in-the-maxim-2022-virtual-growth-conference/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2021-year-end-operational-highlights-and-financial-results/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-completes-acquisition-of-vcn-biosciences/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-host-conference-call-and-webcast-to-discuss-2021-year-end-operational-highlights-and-financial-results/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-2022-bio-ceo-investor-conference/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-vcn-biosciences-vcn-01-receives-orphan-drug-designation-for-retinoblastoma-from-the-u-s-fda/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-b-riley-securities-oncology-conference-on-january-28-2022/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-planned-transformative-acquisition-of-vcn-biosciences-developer-of-a-novel-oncolytic-virus-platform-targeting-pancreatic-and-other-solid-tumors/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-third-quarter-2021-operational-highlights-and-financial-results-conference-call-to-be-held-today-at-430-pm-et/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2021-third-quarter-operational-highlights-and-financial-results-on-november-3-2021/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-initiation-of-a-phase-1-multiple-ascending-dose-clinical-trial-for-syn-020-intestinal-alkaline-phosphatase/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-second-adjournment-of-annual-meeting-of-shareholders-due-to-lack-of-quorum/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-adjournment-of-annual-meeting-of-shareholders-due-to-lack-of-quorum/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-second-quarter-2021-operational-highlights-and-financial-results-conference-call-to-be-held-today-at-430-pm-et/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-expands-option-for-an-exclusive-license-agreement-with-massachusetts-general-hospital/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2021-second-quarter-operational-highlights-and-financial-results-on-august-5-2021/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-provides-update-on-syn-020-intestinal-alkaline-phosphatase-phase-1-single-ascending-dose-clinical-trial/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-regains-compliance-with-nyse-american-continued-listing-standards/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2021-first-quarter-operational-highlights-and-financial-results/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2021-first-quarter-operational-highlights-and-financial-results-on-may-5-2021/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-first-patient-dosed-in-phase-1b-2a-clinical-trial-of-syn-004-ribaxamase-in-allogeneic-hematopoietic-cell-transplant-recipients/ 2022-10-06T11:16:06+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-first-six-participants-dosed-in-phase-1a-clinical-trial-of-syn-020-intestinal-alkaline-phosphatase/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2020-year-end-operational-highlights-and-financial-results/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2020-year-end-operational-highlights-and-financial-results-on-march-4-2021/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-washington-university-school-of-medicine-in-st-louis-irb-approval-of-the-syn-004-ribaxamase-phase-1b-2a-clinical-protocol/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-extension-of-compliance-plan-period-by-nyse-american/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-engages-a-g-p-alliance-global-partners-as-advisor-to-assist-in-evaluating-strategic-options/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-welcomes-senior-biotech-executive-john-monahan-phd-to-board-of-directors/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2020-third-quarter-operational-highlights-and-financial-results/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2020-third-quarter-operational-highlights-and-financial-results-on-november-10-2020/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-provides-update-on-investigator-sponsored-phase-2b-clinical-study-of-syn-010-in-ibs-c-patients/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2020-second-quarter-operational-highlights-and-financial-results/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-fda-clearance-of-investigational-new-drug-application-for-syn-020-intestinal-alkaline-phosphatase-iap/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2020-second-quarter-operational-highlights-and-financial-results-on-august-6-2020/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-submission-of-ind-application-to-u-s-fda-for-syn-020-intestinal-alkaline-phosphatase/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-enters-into-exclusive-option-to-license-intellectual-property-for-use-of-syn-020-to-treat-and-prevent-age-related-metabolic-and-inflammatory-diseases/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2020-first-quarter-operational-highlights-and-financial-results/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2020-first-quarter-operational-highlights-and-financial-results-on-may-5-2020/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2019-year-end-operational-highlights-and-financial-results/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2019-year-end-operational-highlights-and-financial-results-on-february-20-2020/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-acceptance-of-compliance-plan-by-nyse-american/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-2020-bio-ceo-investor-conference/ 2022-10-06T11:16:07+00:00 https://therivabio.com/press_releases/synthetic-biologics-receives-fda-guidance-at-type-c-meeting-for-syn-004-ribaxamase-phase-1b-2a-clinical-trial-in-allogeneic-hct-recipients/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-on-nyse-american-noncompliance-notice-and-compliance-plan/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-third-quarter-2019-operational-highlights-and-financial-results/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2019-third-quarter-operational-highlights-and-financial-results-on-november-4-2019/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-strengthens-u-s-patent-coverage-of-syn-010-intended-for-the-novel-treatment-of-irritable-bowel-syndrome-with-constipation-ibs-c/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-second-quarter-2019-operational-highlights-and-financial-results/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2019-second-quarter-operational-highlights-and-financial-results-on-august-8-2019/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-regains-compliance-with-nyse-american-continued-listing-standards-2/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-first-quarter-2019-operational-highlights-and-financial-results/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2019-first-quarter-operational-highlights-and-financial-results-on-may-8-2019/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2018-year-end-operational-highlights-and-financial-results/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2018-year-end-operational-highlights-and-financial-results-on-february-27-2019/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-first-two-patients-enrolled-in-phase-2b-investigator-sponsored/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-positive-outcome-of-end-of-phase-2-meeting-with-fda-on-syn-004-ribaxamase-development/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-third-quarter-2018-operational-highlights-and-financial-results/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-third-quarter-2018-operational-highlights-and-financial-results-on-november-8-2018/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-closing-of-18639000-public-offering/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-prices-18000000-public-offering/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-agreement-with-cedars-sinai-medical-center-for-an-investigator-sponsored-clinical-study-of-syn-010-for-the-treatment-of-ibs-c/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-20th-annual-rodman-renshaw-global-investment-conference/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-second-quarter-2018-operational-highlights-and-financial-results/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-reverse-stock-split-2/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-second-quarter-2018-operational-highlights-and-financial-results-on-august-8-2018/ 2022-10-06T11:16:08+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-acceptance-of-compliance-plan-by-nyse-american-2/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-first-quarter-2018-operational-highlights-and-financial-results/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-first-quarter-2018-operational-highlights-and-financial-results-on-may-8-2018/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-provides-update-on-development-of-syn-004-ribaxamase-for-the-prevention-of-c-difficile-infection/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-on-nyse-american-noncompliance-notice-and-compliance-plan-2/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2017-year-end-operational-highlights-and-financial-results/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2017-year-end-operational-highlights-and-financial-results-on-february-22-2018/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-biotech-showcase-2018-conference/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-management-changes/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-third-quarter-2017-operational-highlights-and-financial-results/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-third-quarter-2017-operational-highlights-and-financial-results-on-november-1-2017/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-closing-of-12-million-convertible-preferred-stock-financing/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-participation-at-the-19th-annual-rodman-renshaw-global-investment-conference-in-new-york-city-september-10-12-2017/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-second-quarter-2017-operational-highlights-and-financial-results/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-second-quarter-2017-operational-highlights-and-financial-results-on-august-3-2017/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-allowance-of-key-u-s-patent-covering-syn-010-intended-for-the-novel-treatment-of-irritable-bowel-syndrome-with-constipation-ibs-c/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/syn-004-ribaxamase-receives-breakthrough-therapy-designation-from-u-s-food-and-drug-administration-for-prevention-of-clostridium-difficile-infection/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-first-quarter-2017-operational-highlights-and-financial-results/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-first-quarter-2017-operational-highlights-and-financial-results-on-may-4-2017/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-preclinical-data-demonstrating-syn-005-provides-protection-from-pertussis-in-neonatal-animal-study/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-29th-annual-roth-conference/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2016-year-end-operational-highlights-and-financial-results/ 2022-10-06T11:16:09+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2016-year-end-operational-highlights-and-financial-results-on-march-2-2017/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-2017-bio-ceo-investor-conference/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-confirms-key-features-of-pivotal-phase-2b-3-trial-of-syn-010-pursuant-to-consultations-with-fda/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-syn-004-ribaxamase-achieves-primary-endpoint-in-phase-2b-trial-for-c-difficile-infection-cdi/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-biotech-showcase-2017-conference/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-granting-of-u-s-composition-of-matter-patent-for-syn-005-designed-for-the-treatment-and-prevention-of-pertussis-whooping-cough/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-participation-in-two-upcoming-investor-conferences/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-closing-of-public-offering-of-common-stock-and-warrants/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-pricing-of-public-offering-of-common-stock-and-warrants/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-commencement-of-public-offering-of-common-stock-and-warrants/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-third-quarter-2016-operational-highlights-and-financial-results/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-third-quarter-2016-operational-highlights-and-financial-results-on-november-1-2016/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-awarded-research-contract-from-centers-for-disease-control-and-prevention-cdc-for-microbiome-assessment-and-intervention-to-address-antibiotic-resistance/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-completion-of-enrollment-for-phase-2b-proof-of-concept-clinical-trial-for-syn-004-ribaxamase-for-the-prevention-of-clostridium-difficile-infection-antibiotic-associate/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-second-quarter-2016-operational-highlights-and-financial-results/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-completion-of-end-of-phase-2-meeting-with-fda-for-syn-010-intended-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-ibs-c/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-second-quarter-2016-operational-highlights-and-financial-results-on-august-3-2016/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-granting-of-european-and-u-s-composition-of-matter-patents-for-ribaxamase/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-receives-usan-approval-for-generic-name-ribaxamase-for-phase-2-drug-candidate-syn-004/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-2nd-annual-cantor-fitzgerald-healthcare-conference/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-detailed-data-from-two-syn-010-phase-2-clinical-trials-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-ibs-c/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-host-post-ddw-2016-conference-call-to-recap-syn-010-phase-2-clinical-trial-results-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-ibs-c/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-positive-topline-results-from-second-phase-2a-clinical-trial-of-syn-004-for-the-prevention-of-c-difficile-infection-and-antibiotic-associated-diarrhea/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/isaac-j-bright-md-joins-synthetic-biologics-as-vice-president-corporate-development/ 2022-10-06T11:16:10+00:00 https://therivabio.com/press_releases/synthetic-biologics-appoints-deb-mathews-pharmd-as-vice-president-medical-affairs/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-first-quarter-2016-operational-highlights-and-financial-results/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-first-quarter-2016-operational-highlights-and-financial-results-on-may-5-2016/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2015-year-end-operational-highlights-and-financial-results/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-28th-annual-roth-conference/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-2015-year-end-results-on-march-10-2016/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-further-u-s-patent-successes-covering-syn-004-intended-for-the-prevention-of-c-difficile-infection-and-antibiotic-associated-diarrhea/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-the-allowance-of-key-u-s-patent-covering-syn-010-intended-for-the-novel-treatment-of-irritable-bowel-syndrome-with-constipation-ibs-c/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-participate-in-fireside-chat-at-rbc-capital-markets-global-healthcare-conference/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-2016-bio-ceo-investor-conference/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-results-of-independent-third-party-evaluations-of-trimesta-data-from-investigator-sponsored-phase-2-clinical-trial-for-relapsing-remitting-multiple-sclerosis/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-positive-topline-data-from-second-phase-2-clinical-trial-of-syn-010-in-patients-with-irritable-bowel-syndrome-with-constipation-ibs-c/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-biotech-showcase-2016-conference/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-syn-010-lowered-breath-methane-and-improved-stool-frequency-in-a-phase-2-four-week-study-in-patients-with-irritable-bowel-syndrome-with-constipation-ibs-c/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-webcast-microbiome-clinical-program-seminar/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-positive-topline-results-from-first-phase-2a-clinical-trial-of-syn-004-the-companys-candidate-for-the-prevention-of-c-difficile-infection/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-that-data-from-the-phase-2-trimesta-clinical-trial-for-relapsing-remitting-multiple-sclerosis-were-published-by-lead-principal-investigator/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-issuance-of-first-key-u-s-patent-directly-covering-syn-010-the-companys-novel-candidate-for-irritable-bowel-syndrome-with-constipation-ibs-c/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-host-microbiome-clinical-program-seminar-in-new-york-city/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-third-quarter-2015-financial-results-and-operational-highlights/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/grant-awarded-to-synthetic-biologics-academic-collaborator-to-fund-further-evaluation-of-monoclonal-antibody-for-the-prevention-of-whooping-cough-pertussis/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-novel-irritable-bowel-syndrome-with-constipation-ibs-c-program-featured-in-american-college-of-gastroenterology-poster/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-third-quarter-results-on-november-5-2015/ 2022-10-06T11:16:11+00:00 https://therivabio.com/press_releases/synthetic-biologics-initiates-second-syn-010-phase-2-clinical-trial-intended-to-treat-irritable-bowel-syndrome-with-constipation-ibs-c/ 2022-10-06T11:16:12+00:00 https://therivabio.com/press_releases/synthetic-biologics-appoints-raymond-stapleton-phd-as-senior-vice-president-manufacturing/ 2022-10-06T11:16:12+00:00 https://therivabio.com/press_releases/synthetic-biologics-initiates-syn-004-phase-2b-proof-of-concept-clinical-trial/ 2022-10-06T11:16:12+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-first-analysis-demonstrating-syn-004s-ability-to-protect-the-microbiome-from-damage-caused-by-iv-antibiotics-in-a-humanized-pig-model/ 2022-10-06T11:16:12+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-second-quarter-2015-financial-results-and-operational-highlights/ 2022-10-06T11:16:12+00:00 https://therivabio.com/press_releases/intrexon-and-synthetic-biologics-enter-ecc-to-develop-novel-biotherapeutics-for-treatment-of-phenylketonuria/ 2022-10-06T11:16:12+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-second-quarter-results-on-august-10-2015/ 2022-10-06T11:16:12+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-closing-of-recent-equity-offering-and-exercise-in-full-of-underwriters-over-allotment-option/ 2022-10-06T11:16:12+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-pricing-of-40-0-million-public-offering/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-public-offering-of-common-stock/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-initiates-syn-010-phase-2-clinical-trial-to-treat-irritable-bowel-syndrome-with-constipation-ibs-c/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/first-participant-dosed-in-synthetic-biologics-second-phase-2a-clinical-trial-to-protect-the-microbiome-and-prevent-c-difficile/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-presents-initial-data-validating-platform-expansion-to-cover-carbapenem-antibiotics/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-expands-clinical-regulatory-leadership-team-with-addition-of-klaus-gottlieb-md-facg/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-host-microbiome-analyst-investor-meeting/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-syn-004-microbiome-protecting-preclinical-data-highlighted-in-late-breaking-poster-at-digestive-disease-week-2015/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-novel-syn-010-preclinical-data-featured-in-digestive-disease-week-poster/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-first-quarter-2015-financial-results-and-operational-highlights/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/maureen-early-named-vice-president-commercial-of-synthetic-biologics/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/steven-shallcross-named-chief-financial-officer-of-synthetic-biologics/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/posters-at-eccmid-2015-highlight-preclinical-data-from-synthetic-biologics-novel-syn-005-monoclonal-antibody-combination-for-the-treatment-and-prophylaxis-of-whooping-cough-pertussis/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-syn-004-clinical-data-for-protection-of-microbiome-selected-for-poster-presentation-at-american-society-of-microbiology-2015/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-initiates-phase-2a-clinical-trial-of-syn-004-to-protect-the-microbiome-and-prevent-c-difficile/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-positive-pharmacokinetics-data-from-phase-1a-and-1b-trials-of-syn-004-to-protect-the-microbiome-and-prevent-c-difficile-infection/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-year-end-2014-financial-results-and-operational-highlights/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-syn-004-data-for-protection-of-microbiome-selected-for-late-breaking-poster-presentation-at-digestive-disease-week-2015/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-year-end-2014-financial-results/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-27th-annual-roth-conference/ 2022-10-06T11:16:13+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-two-poster-presentations-of-novel-monoclonal-antibody-combination-for-treatment-of-whooping-cough-pertussis-at-eccmid-2015/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-poster-presentation-of-c-ibs-candidate-therapy-data-at-digestive-disease-week-2015/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-positive-topline-results-from-phase-1b-trial-of-syn-004-to-protect-the-microbiome-and-prevent-c-difficile-infection/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-2015-bio-ceo-investor-conference/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-biotech-showcase-2015-conference/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-first-patient-dosed-in-phase-1b-clinical-trial-of-syn-004-for-the-prevention-of-c-difficile-infection/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-positive-topline-results-from-phase-1a-trial-of-syn-004-for-the-prevention-of-c-difficile-infection/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-first-patient-dosed-in-phase-1a-clinical-trial-of-syn-004-for-the-prevention-of-c-difficile-infection/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-safe-to-proceed-under-ind-to-initiate-clinical-trials-of-syn-004-for-the-prevention-c-difficile-infection/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-third-quarter-2014-financial-results-and-operational-highlights/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-third-quarter-2014-financial-results/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-allowance-of-key-u-s-composition-of-matter-patent-for-c-difficile-program/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-appoints-prominent-gastrointestinal-gi-key-opinion-leaders-to-irritable-bowel-syndrome-ibs-clinical-advisory-board/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-raise-20-7-million-in-registered-direct-offering/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-statin-class-candidate-for-constipation-predominant-irritable-bowel-syndrome-detailed-at-companys-investor-day/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-receives-orphan-drug-designation-for-syn-005-treatment-for-whooping-cough-pertussis/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-host-phase-ii-trimesta-for-multiple-sclerosis-conference-call/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-webcast-september-16-2014-irritable-bowel-syndrome-ibs-investor-day/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-highlights-syn-005-data-presented-at-the-54th-icaac-from-novel-whooping-cough-pertussis-program/ 2022-10-06T11:16:14+00:00 https://therivabio.com/press_releases/synthetic-biologics-highlights-new-data-from-c-difficile-program-presented-at-the-54th-icaac/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-16th-annual-rodman-renshaw-global-investment-conference-in-new-york-city/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-initiate-clinical-trials-of-syn-004-in-4q-2014-to-prevent-potentially-deadly-c-difficile-infections/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-and-fujifilm-diosynth-biotechnologies-uk-announce-significant-improvement-in-api-manufacturing-of-syn-004-for-the-prevention-of-c-difficile/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-presentation-of-poster-for-syn-004-c-difficile-program-at-idweek-2014/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-late-breaking-poster-presentation-for-c-difficile-program-at-54th-icaac/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-second-quarter-2014-financial-results-and-operational-highlights/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-host-irritable-bowel-syndrome-ibs-investor-day/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-academic-collaborator-to-present-novel-monoclonal-antibody-combination-for-treatment-of-whooping-cough-pertussis-at-54th-icaac/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-second-quarter-2014-financial-results/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-on-track-to-initiate-clinical-program-for-syn-004-to-protect-against-c-difficile/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/expanded-data-on-disability-and-cognitive-improvements-in-phase-ii-study-of-synthetic-biologics-trimesta-in-multiple-sclerosis-to-be-presented-at-2014-joint-actrims-ectrims-meeting/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-inc-states-that-its-policy-is-not-to-comment-on-unusual-market-activity/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-academic-collaborator-to-present-novel-monoclonal-antibody-combination-for-treating-whooping-cough-pertussis-at-gordon-research-conference/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-forms-clinical-advisory-board-to-support-novel-c-difficile-preventative-program/ 2022-10-06T11:16:15+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-that-licensor-cedars-sinai-finds-eradication-of-gut-methane-improves-insulin-sensitivity-and-lipid-profiles-in-study-of-pre-diabetic-obese-patients/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-and-enterome-bioscience-collaborate-on-microbiome-research-to-support-synthetic-biologics-c-difficile-program/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-3rd-annual-marcum-llp-microcap-conference/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-first-quarter-2014-financial-results-and-operational-highlights/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-first-quarter-2014-financial-results/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-recent-international-patents-that-bolster-its-c-difficile-program/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-discuss-phase-ii-results-of-oral-estriol-candidate-trimesta-for-relapsing-remitting-multiple-sclerosis-in-women/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-ucla-announcement-of-preliminary-positive-topline-efficacy-and-safety-results-from-investigator-led-phase-ii-study-of-trimesta-for-relapsing-remitting-multiple-scl/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-preclinical-data-to-support-clinical-development-of-novel-pertussis-therapeutic/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-appoints-mark-pimentel-m-d-chairman-of-new-irritable-bowel-syndrome-clinical-advisory-board/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-year-end-2013-financial-results-and-operational-update/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-year-end-2013-financial-results/ 2022-10-06T11:16:16+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-issuance-of-u-s-patent-adding-another-layer-of-protection-for-the-use-of-oral-estriol-candidate-trimesta-for-multiple-sclerosis/ 2022-10-06T11:16:17+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-26th-annual-roth-conference/ 2022-10-06T11:16:17+00:00 https://therivabio.com/press_releases/synthetic-biologics-board-of-directors-accepts-resignation-of-long-standing-founder-and-board-member/ 2022-10-06T11:16:17+00:00 https://therivabio.com/press_releases/synthetic-biologics-inc-states-that-its-policy-is-not-to-comment-on-unusual-market-activity-2/ 2022-10-06T11:16:17+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-rhonda-voskuhl-m-d-to-present-trimesta-phase-ii-multiple-sclerosis-clinical-trial-results-at-the-2014-aan-annual-meeting/ 2022-10-06T11:16:17+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-2014-bio-ceo-investor-conference/ 2022-10-06T11:16:17+00:00 https://therivabio.com/press_releases/synthetic-biologics-strengthens-clinical-regulatory-team-to-support-expanding-pipeline-of-infectious-disease-programs/ 2022-10-06T11:16:17+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-biotech-showcase-2014-conference/ 2022-10-06T11:16:17+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-7th-annual-onemedforum-san-francisco-2014-conference/ 2022-10-06T11:16:17+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-closing-of-public-offering-of-common-stock/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-exercise-of-underwriters-over-allotment-option/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-pricing-of-public-offering-of-common-stock/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-pricing-of-public-offering-of-common-stock-2/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-proposed-public-offering-of-common-stock/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-and-intrexon-corporation-initiate-development-of-novel-biologics-for-a-subset-of-patients-suffering-from-irritable-bowel-syndrome-ibs/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-webcast-conference-call-set-for-900-a-m-est-this-morning-december-9th/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-enters-into-license-with-cedars-sinai-medical-center-to-develop-novel-anti-infective-approaches-for-irritable-bowel-syndrome-ibs-obesity-and-diabetes/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-ld-micro-vi-main-event-conference-in-los-angeles/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-syn-004-for-the-prevention-of-c-difficile-infections-named-a-top-project-to-watch-by-elsevier-business-intelligence/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-third-quarter-2013-financial-results-and-operational-update/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-third-quarter-2013-financial-results/ 2022-10-06T11:16:18+00:00 https://therivabio.com/press_releases/synthetic-biologics-initiates-manufacturing-of-syn-004-for-use-in-preclinical-and-clinical-trials-to-target-the-prevention-of-c-difficile-infections/ 2022-10-06T11:16:19+00:00 https://therivabio.com/press_releases/synthetic-biologics-responds-to-recent-cdc-report-on-threat-of-super-bugs/ 2022-10-06T11:16:19+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-first-global-life-sciences-conference-in-warsaw-poland/ 2022-10-06T11:16:19+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-15th-annual-rodman-renshaw-global-investment-conference-in-new-york-city/ 2022-10-06T11:16:19+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-second-quarter-2013-financial-results-and-operational-update/ 2022-10-06T11:16:19+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-report-second-quarter-2013-financial-results/ 2022-10-06T11:16:19+00:00 https://therivabio.com/press_releases/former-pfizer-wyeth-global-infectious-disease-pharmaceutical-executive-lewis-barrett-appointed-senior-vice-president-commercial-strategy-of-synthetic-biologics-inc/ 2022-10-06T11:16:19+00:00 https://therivabio.com/press_releases/synthetic-biologics-initiates-manufacturing-process-for-c-difficile-infectious-disease-program/ 2022-10-06T11:16:19+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-onemedforum-new-york-2013/ 2022-10-06T11:16:19+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-host-multiple-sclerosis-estriol-investor-day-in-new-york-city-on-june-25-2013/ 2022-10-06T11:16:20+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-2nd-annual-marcum-llp-microcap-conference/ 2022-10-06T11:16:20+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-first-quarter-2013-financial-results/ 2022-10-06T11:16:20+00:00 https://therivabio.com/press_releases/synthetic-biologics-reiterates-that-the-infectious-disease-collaboration-with-intrexon-remains-in-effect/ 2022-10-06T11:16:21+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-year-end-2012-financial-results/ 2022-10-06T11:16:21+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-issuance-of-u-s-patent-covering-combination-of-estriol-and-copaxone-for-multiple-sclerosis/ 2022-10-06T11:16:21+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-25th-annual-roth-conference/ 2022-10-06T11:16:21+00:00 https://therivabio.com/press_releases/infectious-disease-specialist-brad-spellberg-m-d-joins-synthetic-biologics-scientific-advisory-board/ 2022-10-06T11:16:21+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-that-flupirtine-sublicensee-meda-ab-to-initiate-phase-ii-fibromyalgia-clinical-trial-in-u-s/ 2022-10-06T11:16:21+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-2013-bio-ceo-investor-conference/ 2022-10-06T11:16:21+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-onemedforum-san-francisco-2013/ 2022-10-06T11:16:22+00:00 https://therivabio.com/press_releases/synthetic-biologics-and-intrexon-corporation-initiate-development-of-monoclonal-antibodies-for-whooping-cough-pertussis/ 2022-10-06T11:16:22+00:00 https://therivabio.com/press_releases/synthetic-biologics-closes-deal-for-acquisition-of-c-difficile-infectious-disease-program/ 2022-10-06T11:16:22+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-the-fifth-annual-ld-micro-conference-in-los-angeles/ 2022-10-06T11:16:22+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-third-quarter-2012-financial-results/ 2022-10-06T11:16:22+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-acquire-clinical-stage-c-difficile-infectious-disease-program/ 2022-10-06T11:16:22+00:00 https://therivabio.com/press_releases/synthetic-biologics-initiates-development-of-monoclonal-antibodies-for-treatment-of-acinetobacter-infections/ 2022-10-06T11:16:22+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-second-quarter-2012-financial-results/ 2022-10-06T11:16:22+00:00 https://therivabio.com/press_releases/synthetic-biologics-and-intrexon-corporation-enter-worldwide-exclusive-collaboration-for-infectious-diseases/ 2022-10-06T11:16:22+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-first-quarter-2012-financial-results/ 2022-10-06T11:16:22+00:00 https://therivabio.com/press_releases/synthetic-biologics-appoints-carol-reed-m-d-as-senior-vice-president-of-clinical-regulatory-affairs/ 2022-10-06T11:16:22+00:00 https://therivabio.com/press_releases/synthetic-biologics-appoints-jeffrey-j-kraws-as-independent-chairman/ 2022-10-06T11:16:23+00:00 https://therivabio.com/press_releases/synthetic-biologics-launches-free-investor-relations-mobile-application/ 2022-10-06T11:16:23+00:00 https://therivabio.com/press_releases/synthetic-biologics-appoints-michael-kaleko-m-d-ph-d-as-scientific-director/ 2022-10-06T11:16:23+00:00 https://therivabio.com/press_releases/synthetic-biologics-reports-2011-year-end-financial-results/ 2022-10-06T11:16:23+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-completion-of-enrollment-in-164-patient-clinical-trial-of-oral-trimesta-for-multiple-sclerosis/ 2022-10-06T11:16:23+00:00 https://therivabio.com/press_releases/synthetic-biologics-to-present-at-roth-annual-growth-stock-conference/ 2022-10-06T11:16:23+00:00 https://therivabio.com/press_releases/adeona-becomes-synthetic-biologics-inc/ 2022-10-06T11:16:23+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-positive-outcome-of-data-and-safety-monitoring-committee-dsmc-review-in-phase-1b-2a-clinical-trial-of-syn-004-ribaxamase-in-allogeneic-hematopoietic-cell-transplant-r/ 2022-10-11T16:55:19+00:00 https://therivabio.com/press_releases/synthetic-biologics-announces-presentation-at-siop-international-society-of-pediatric-oncology-on-new-preclinical-data-supporting-evaluation-of-vcn-01-and-topotecan-for-the-treatment-of-refractory-ret/ 2022-10-11T19:00:35+00:00 https://therivabio.com/press_releases/synthetic-biologics-rebrands-as-theriva-biologics/ 2022-10-12T08:05:30+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-key-progress-in-virage-an-ongoing-multinational-phase-2b-trial-of-vcn-01-in-combination-with-chemotherapy-in-pancreatic-ductal-adenocarcinoma/ 2023-08-09T15:06:17+00:00 https://therivabio.com/press_releases/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-second-quarter-2023-operational-highlights-and-financial-results/ 2023-08-17T09:39:26+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-orphan-drug-designation-granted-by-the-u-s-fda-for-vcn-01-for-the-treatment-of-pancreatic-cancer/ 2023-08-17T09:39:57+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-appointment-of-ramon-alemany-ph-d-to-senior-vice-president-of-discovery/ 2023-08-17T09:40:10+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-first-quarter-2023-operational-highlights-and-financial-results/ 2023-08-17T09:40:35+00:00 https://therivabio.com/press_releases/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results/ 2023-08-17T09:40:51+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-presentation-of-data-from-cohort-1-of-the-phase-1b-2a-clinical-trial-of-syn-004-ribaxamase-in-allogeneic-hematopoietic-cell-transplant-recipients/ 2023-08-17T09:41:02+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-fourth-quarter-and-full-year-2022-operational-highlights-and-financial-results/ 2023-08-17T09:41:14+00:00 https://therivabio.com/press_releases/theriva-biologics-to-reschedule-conference-call-and-webcast-to-discuss-fourth-quarter-and-full-year-2022-operational-highlights-and-financial-results/ 2023-08-17T09:41:24+00:00 https://therivabio.com/press_releases/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-fourth-quarter-and-full-year-2022-operational-highlights-and-financial-results/ 2023-08-17T09:41:34+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-presentation-of-safety-and-pharmacokinetic-data-from-cohort-1-of-the-phase-1b-2a-clinical-trial-of-syn-004-ribaxamase-in-allogeneic-hematopoietic-cell-transplant-recipien/ 2023-08-17T09:41:42+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-first-patient-dosed-in-virage-a-phase-2b-trial-of-systemically-administered-vcn-01-in-combination-with-chemotherapy-in-pancreatic-ductal-adenocarcinoma/ 2023-08-17T09:41:57+00:00 https://therivabio.com/press_releases/theriva-biologics-to-participate-in-the-b-riley-securities-3rd-annual-oncology-conference/ 2023-08-17T09:42:06+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-dosing-of-first-patient-in-the-investigator-sponsored-phase-1-trial-of-vcn-01-an-intravenous-oncolytic-adenovirus-in-patients-with-brain-tumors/ 2023-08-17T09:42:14+00:00 https://therivabio.com/press_releases/theriva-biologics-to-participate-in-upcoming-investor-conferences/ 2023-08-17T09:42:23+00:00 https://therivabio.com/press_releases/theriva-biologics-to-reschedule-conference-call-and-webcast-to-discuss-third-quarter-2022-operational-highlights-and-financial-results/ 2023-08-17T09:42:33+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-third-quarter-2022-operational-highlights-and-financial-results/ 2023-08-17T09:42:43+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-first-patient-dosed-in-second-cohort-of-phase-1b-2a-clinical-trial-of-syn-004-ribaxamase-in-allogeneic-hematopoietic-cell-transplant-recipients/ 2023-08-17T09:43:05+00:00 https://therivabio.com/press_releases/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-third-quarter-2022-operational-highlights-and-financial-results/ 2023-08-17T09:43:15+00:00 https://therivabio.com/press_releases/theriva-biologics-to-host-key-opinion-leader-webinar-on-lead-program-vcn-01-and-advancing-unique-oncolytic-virus-therapeutics/ 2023-08-17T09:43:24+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-presentation-at-the-14th-international-oncolytic-virotherapy-ivoc-conference-describing-phase-1-investigator-sponsored-study-evaluating-vcn-01-in-combination-with-durvalu/ 2023-08-17T09:43:32+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-second-quarter-2023-operational-highlights-and-financial-results/ 2023-08-27T10:48:34+00:00 https://therivabio.com/press_releases/theriva-biologics-to-participate-in-the-emerging-growth-conference/ 2023-09-28T09:14:28+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-presentation-at-esmo-congress-2023-featuring-survival-outcomes-in-phase-1-study-evaluating-vcn-01-in-combination-with-durvalumab-in-patients-with-recurrent-metasta/ 2023-10-16T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-presents-survival-outcomes-data-from-phase-1-study-evaluating-vcn-01-in-combination-with-durvalumab-in-patients-with-recurrent-metastatic-squamous-cell-carcinoma-of-the-head/ 2023-10-23T07:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-to-participate-in-the-bio-europe-conference/ 2023-11-02T04:15:00+00:00 https://therivabio.com/press_releases/theriva-biologics-and-sant-joan-de-deu-barcelona-childrens-hospital-advance-strategic-collaboration-to-explore-the-combination-of-vcn-01-with-topoisomerase-inhibitors-to-treat-cancer/ 2023-11-02T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-third-quarter-2023-operational-highlights-and-financial-results/ 2023-11-06T04:05:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-third-quarter-2023-operational-highlights-and-financial-results/ 2023-11-13T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-to-participate-in-the-b-riley-securities-annual-oncology-conference/ 2024-01-16T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-positive-recommendation-from-the-independent-data-monitoring-committee-of-virage-the-phase-2b-clinical-trial-of-vcn-01-in-combination-with-chemotherapy-for-metastatic-pan-2/ 2024-02-07T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-to-participate-in-the-bio-europe-spring-conference/ 2024-03-11T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-full-year-2023-operational-highlights-and-financial-results/ 2024-03-19T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-full-year-2023-operational-highlights-and-financial-results/ 2024-03-25T07:30:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-presentation-at-the-american-society-for-cell-and-gene-therapy-27th-annual-meeting/ 2024-04-08T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-to-present-preclinical-data-supporting-the-potential-synergy-of-vcn-01-and-first-line-pancreatic-cancer-chemotherapy-regimens-at-the-american-society-for-cell-and-gene-thera/ 2024-04-24T10:28:34+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-positive-topline-data-from-investigator-sponsored-phase-1-trial-of-intravitreal-vcn-01-in-pediatric-patients-with-refractory-retinoblastoma/ 2024-04-24T10:30:22+00:00 https://therivabio.com/press_releases/theriva-biologics-to-discuss-the-trial-design-for-virage-a-phase-2b-clinical-study-of-systemically-administered-vcn-01-in-combination-with-chemotherapy-in-pancreatic-ductal-adenocarcinoma/ 2024-04-25T08:15:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-first-quarter-2024-operational-highlights-and-financial-results/ 2024-05-07T07:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-to-participate-in-the-a-g-p-virtual-healthcare-conference/ 2024-05-14T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-fast-track-designation-granted-by-the-u-s-fda-for-vcn-01-for-the-treatment-of-metastatic-pancreatic-cancer/ 2024-05-23T08:15:00+00:00 https://therivabio.com/press_releases/theriva-biologics-receives-rare-pediatric-drug-designation-by-the-u-s-fda-for-vcn-01-for-the-treatment-of-retinoblastoma/ 2024-07-31T08:15:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-second-quarter-2024-operational-highlights-and-financial-results/ 2024-08-13T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-reverse-stock-split/ 2024-08-16T04:05:00+00:00 https://therivabio.com/press_releases/theriva-biologics-awarded-manufacturing-funding-from-the-spanish-governments-national-knowledge-transfer-program/ 2024-09-16T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-achieves-target-patient-enrollment-in-the-virage-phase-2b-trial-of-vcn-01-with-gemcitabine-nab-paclitaxel-for-the-treatment-of-metastatic-pancreatic-cancer/ 2024-09-23T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-pricing-of-2-5-million-public-offering/ 2024-09-26T09:06:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-positive-outcome-of-data-and-safety-monitoring-committee-dsmc-review-in-phase-1b-2a-clinical-trial-of-syn-004-ribaxamase-in-allogeneic-hematopoietic-cell-trans/ 2024-10-03T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-orphan-medicinal-product-designation-granted-by-the-european-commission-to-vcn-01-for-the-treatment-of-retinoblastoma/ 2024-10-16T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-selected-as-finalist-in-international-competition-for-merck-kgaas-emea-advance-biotech-grant/ 2024-10-31T04:05:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-third-quarter-2024-operational-highlights-and-financial-results/ 2024-11-12T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-u-s-fda-guidance-on-design-of-phase-3-study-of-vcn-01-for-the-treatment-of-metastatic-pancreatic-cancer/ 2024-12-05T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual/ 2025-03-05T04:05:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-full-year-2024-operational-highlights-and-financial-results/ 2025-03-06T04:10:00+00:00 https://therivabio.com/press_releases/theriva-biologics-to-present-at-the-2025-neauxcancer-conference/ 2025-03-19T08:10:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-positive-outcomes-from-the-second-meeting-of-the-independent-data-monitoring-committee-for-virage-the-companys-phase-2b-clinical-trial-of-vcn-01-in-combi/ 2025-03-31T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-presentation-of-data-from-the-phase-1b-2a-clinical-trial-of-syn-004-ribaxamase-in-allogeneic-hematopoietic-cell-transplant-recipients/ 2025-04-10T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-primary-endpoints-for-efficacy-and-safety-achieved-in-virage-phase-2b-clinical-trial-of-vcn-01-with-gemcitabine-nab-paclitaxel-in-newly-diagnosed-metastatic-pancre/ 2025-05-07T07:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-pricing-of-7-5-million-public-offering/ 2025-05-07T09:17:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-closing-of-7-5-million-public-offering/ 2025-05-08T04:30:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-first-quarter-2025-operational-highlights-and-financial-results/ 2025-05-14T08:40:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-presentation-of-data-from-vcn-01-retinoblastoma-phase-1-clinical-trial-at-asco-2025-and-investigator-meeting-to-review-topline-data-from-the-virage-phase-2b-trial/ 2025-05-27T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-second-quarter-2025-operational-highlights-and-financial-results/ 2025-08-11T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-presentation-describing-next-generation-oncolytic-adenovirus-vcn-12-at-the-32nd-annual-congress-of-the-european-society-of-gene-cell-therapy-esgct/ 2025-10-06T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-upcoming-presentations-at-medical-meetings/ 2025-10-13T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-a-warrant-inducement-transaction-for-4-0-million-in-gross-proceeds/ 2025-10-16T08:11:00+00:00 https://therivabio.com/press_releases/theriva-biologics-provides-response-to-unusual-market-action/ 2025-10-24T02:31:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-third-quarter-2025-operational-highlights-and-financial-results/ 2025-11-12T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-positive-scientific-advice-from-the-european-medicines-agency-ema-on-the-design-of-a-phase-3-trial-of-vcn-01-in-metastatic-pancreatic-ductal-adenocarcinoma-pdac/ 2025-12-29T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-upcoming-presentation-of-data-from-vcn-01-retinoblastoma-phase-1-clinical-trial-at-apao-2026/ 2026-02-03T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-licenses-syn-020-to-rasayana-therapeutics-for-multiple-indications/ 2026-02-18T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-full-year-2025-operational-highlights-and-financial-results/ 2026-03-12T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-positive-end-of-phase-2-meeting-with-u-s-fda-regarding-the-design-of-a-phase-3-trial-of-vcn-01-in-metastatic-pancreatic-ductal-adenocarcinoma/ 2026-03-23T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-upcoming-presentation-of-additional-data-from-the-virage-phase-2b-clinical-trial-of-vcn-01-in-metastatic-pancreatic-cancer-at-aacr-2026-annual-meeting/ 2026-04-17T04:05:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-upcoming-presentation-of-additional-data-from-the-virage-phase-2b-clinical-trial-of-vcn-01-in-metastatic-pancreatic-cancer-at-aacr-2026-annual-meeting-2/ 2026-04-17T04:05:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-first-quarter-2026-operational-highlights-and-financial-results/ 2026-05-05T04:30:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-results-from-vcn-01-phase-1-clinical-trial-in-head-and-neck-cancer-published-in-clinical-cancer-research/ 2026-06-11T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-regulatory-authorization-to-proceed-with-a-virage2-phase-2a-clinical-trial-to-evaluate-more-frequent-dosing-of-vcn-01-zabilugene-almadenorepvec-in-first-line-pat/ 2026-07-07T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-first-patient-dosed-in-virage2-phase-2a-clinical-trial-to-evaluate-more-frequent-dosing-of-vcn-01-zabilugene-almadenorepvec-in-first-line-patients-with-metastati/ 2026-08-06T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-reports-second-quarter-2026-operational-highlights-and-financial-results/ 2026-08-11T08:00:00+00:00 https://therivabio.com/press_releases/theriva-biologics-announces-publication-of-the-results-from-the-virage-phase-2b-clinical-trial-of-vcn-01-in-metastatic-pancreatic-cancer-published-in-nature-medicine/ 2026-09-30T08:00:00+00:00